Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140

Journal of Pharmaceutical Sciences

Volumn 99, Issue 5, 2010, Pages 2521-2528

  Ghobrial, Oliver ^a,b   Derendorf, Hartmut ^b   Hillman, Jeffrey D ^a  

^a Oragenics Inc   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

ADME; Antiinfectives; Pharmacokinetic pharmacodynamic models; Pharmacokinetics; Preclinical pharmacokinetic

Indexed keywords

DIPHENHYDRAMINE; LANTIBIOTIC; MU 1140; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BACTERICIDAL ACTIVITY; BOLUS INJECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG STRUCTURE; IN VIVO STUDY; INJECTION; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PREMEDICATION; RAT; SIMULATION; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS;

EID: 77951270693     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22015     Document Type: Article

References (22)

1. Amyes SG. 2000. The rise in bacterial resistance is partly because there have been no new classes of antibiotics since the 1960s. BMJ 320:199-200.
2. Jones RN. 2001. Resistance patterns among nosocomial pathogens: Trends over the past few years. Chest 119:397S-404S.
3. CDC. 2001. Campaign to Prevent Antimicrobial Resistance in Healthcare Settings ed.
4. Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Smulders M, Lapetina E, Gemmen E. 2005. The burden of Staphylococcus aureus infections on hospitals in the United States: An analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 165:1756-1761. (Pubitemid 41138964)
5. Shlaes DM. 1992. Vancomycin-resistant bacteria. Infect Control Hosp Epidemiol 13:193-194.
6. Rice LB. 2006. Unmet medical needs in antibacterial therapy. Biochem Pharmacol 71:991-995. (Pubitemid 43306791)
7. Schmidt S, Schuck E, Kumar V, Burkhardt O, Derendorf H. 2007. Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents; minimum inhibitory concentration versus time-kill curves. Expert Opin Drug Discov 2:849-860. (Pubitemid 47296527)
8. Hillman JD, Novak J, Sagura E, Gutierrez JA, Brooks TA, Crowley PJ, Hess M, Azizi A, Leung K, Cvitkovitch D, Bleiweis AS. 1998. Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect Immun 66:2743-2749. (Pubitemid 28261778)
9. Chatterjee C, Paul M, Xie L, van der Donk WA. 2005. Biosynthesis and mode of action of lantibiotics. Chem Rev 105:633-684.
10. Smith L, Hasper H, Breukink E, Novak J, Cerkasov J, Hillman JD, Wilson-Stanford S, Orugunty RS. 2008. Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry 47: 3308-3314. (Pubitemid 351364923)
11. Hasper HE, Kramer NE, Smith JL, Hillman JD, Zachariah C, Kuipers OP, de Kruijff B, Breukink E. 2006. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 313:1636-1637. (Pubitemid 44414037)
12. Ghobrial OG, Derendorf H, Hillman JD. 2009. Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrob Agents 33:70-74.
13. Ghobrial O, Derendorf H, Hillman J. 2009. Serum proteins binding and its effect on the pharmacodynamics of the peptide antibiotic MU1140. (In Preperation)
14. Ghobrial OG, Derendorf H, Hillman JD. 2009. Development and validation of a LC-MS quantification method for the lantibiotic MU1140 in rat plasma. J Pharm Biomed Anal 49:970-975.
15. Yamaoka K, Nakagawa T, Uno T. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175. (Pubitemid 8384279)
16. Smith L, Hillman J. 2008. Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Curr Opin Microbiol 11:401-408.
17. Toke O, Cegelski L, Schaefer J. 2006. Peptide antibiotics in action: Investigation of polypeptide chains in insoluble environments by rotational-echo double resonance. Biochim Biophys Acta 1758:1314-1329. (Pubitemid 44436075)
18. Frick A, Durasin I. 1977. Effect of expansion of extracellular fluid volume on the maximal reabsorptive capacity for inorganic phosphate in parathyroidectomized and intact rats. Pflugers Arch 370:115-119. (Pubitemid 8158539)
19. Larsson M, Ware J. 1983. Effects of isotonic fluid load on plasma water and extracellular fluid volumes in the rat. Eur Surg Res 15:262-267.
20. Sivagnanam S, Deleu D. 2003. Red man syndrome. Crit Care 7:119-120.
21. Bone RC. 1994. Sepsis and its complications: The clinical problem. Crit Care Med 22:S8-S11.
22. Kellner R, Jung G, Horner T, Zahner H, Schnell N, Entian KD, Gotz F. 1988. Gallidermin: A new lanthionine-containing polypeptide antibiotic. Eur J Biochem 177:53-59.